Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer
Phase 1/2 Completed
93 enrolled
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
Phase 3 Completed
2,722 enrolled 14 charts
Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer
Phase 2 Completed
105 enrolled 17 charts
Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients
Phase 3 Completed
429 enrolled
Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer
Phase 3 Completed
2,104 enrolled 11 charts
BETH
Phase 3 Terminated
3,509 enrolled
Tamoxifen in Treating Women With High-Risk Breast Cancer
Phase 3 Completed
672 enrolled
Docetaxel and Epirubicin With and Without G-CSF in Treating Women With Metastatic Breast Cancer
Phase 1 Completed
50 enrolled
PERCHE
Phase 3 Terminated
29 enrolled 6 charts
Lapatinib and Epirubicin in Treating Patients With Metastatic Breast Cancer. ICORG 06-30
Phase 1 Completed
10 enrolled
Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer
Phase 3 Completed
1,856 enrolled
12-93
Phase 3 Completed
452 enrolled
15-95
Phase 3 Completed
344 enrolled
Combination Chemotherapy Before Surgery in Treating Women With Breast Cancer
Phase 1 Completed
15 enrolled
Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine in Early Breast Cancer
Phase 3 Completed
536 enrolled
A Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients With Locally Advanced Breast Cancer
Phase 2 Completed
76 enrolled